U.S. Wireless Telecom Stock News

Dave (DAVE) is back in focus after record third quarter results and a stronger tone around fintech, with recent analyst sentiment and sector headlines prompting many investors to take a fresh look at the stock. See our latest analysis for Dave. At a share price of $239.35, Dave has seen a 21.57% 30 day share price return and a very large 3 year total shareholder return, suggesting momentum has been building as recent record results and sector headlines kept fintech in the spotlight. If Dave’s...

Earlier this week, New Street analyst David Barden upgraded American Tower to a more positive rating, highlighting its long-term tower lease contracts with Dish that run through 2036 and represent about US$200 million in annual payments. The analyst argued that, despite American Tower’s exposure to Dish, the company’s growth profile remains aligned with its historical pattern, suggesting the current market view may not fully reflect its contractual revenue base. Next, we’ll examine how this...

Bentley Systems, Incorporated recently announced that its Blyncsy asset analytics solution is being used in Hawaii’s Eyes on the Road program, which equips 1,000 resident vehicles with high-resolution dash cameras to crowd‑source roadway safety data that is automatically analyzed in the cloud using AI. This collaboration highlights how Bentley is applying AI to turn everyday driving footage into real‑time, actionable insights for transportation asset management and road safety. We’ll now...

Alkami Technology (ALKT) has rolled out its One-Click SDK Manager, a new deployment tool for its digital banking platform that aims to cut friction for developers and financial institutions using its cloud-based services. See our latest analysis for Alkami Technology. The One-Click SDK Manager arrives at a time when Alkami Technology’s share price, at US$22.18, has seen a 7 day share price return decline of 2.20%, while its 1 year total shareholder return of 35.05% decline contrasts with a...

Hamilton Insurance Group recently reported that sales are projected to decline by 1.9% over the next 12 months, while rising costs have worsened its combined ratio and reduced earnings per share, raising questions about near-term profitability. This shift in operating trends highlights how even modest demand softness, when paired with sustained cost pressure, can meaningfully strain an insurer’s underlying economics. We’ll now explore how this weaker sales outlook and rising cost base may...

In the third quarter, New York City-based Summit Street Capital Management increased its position in Core Natural Resources by 81,170 shares, bringing its stake to 342,155 shares, while the company reported strong revenue, net income, adjusted EBITDA, and meaningful free cash flow. Core Natural Resources also returned approximately 100% of that free cash flow to shareholders through repurchases and dividends, underscoring management’s focus on capital returns. We’ll now examine how Summit...

In early January 2026, Iron Mountain disclosed that officer William L. Meaney sold 38,482 shares of common stock for about US$3.2 million, while analysts at Truist Securities reaffirmed a positive outlook on the company’s business mix, including data centers and Asset Lifecycle Management. The combination of insider activity and upbeat analyst commentary around data center leasing, easing restructuring costs, and Asset Lifecycle Management growth has sharpened investor focus on how Iron...

What Voyager Technologies’ recent performance means for investors Voyager Technologies (VOYG) has caught investor attention after a recent mix of short term weakness and stronger month and past 3 months returns, prompting closer scrutiny of how its current valuation lines up with fundamentals. See our latest analysis for Voyager Technologies. With the share price at $31.33 after a 1-day share price decline of 1.26%, the stronger 7-day and 30-day share price returns of 12.78% and 14.30%...

Mercury General (MCY) has drawn fresh attention after its recent trading performance, with the share price around $89.69 and return figures that vary widely between the past month, past 3 months, and longer periods. See our latest analysis for Mercury General. At a recent share price of US$89.69, Mercury General’s short term share price performance has softened slightly, but its 90 day share price return of 11.92% and 1 year total shareholder return of 87.84% point to momentum that has built...

If you are wondering whether W. R. Berkley at around US$68.44 is offering fair value or a potential mispricing, you are not alone. The stock has been fairly flat in the short term, with a 1.3% decline over both 7 and 30 days and year to date, but its return of 23.9% over 1 year, 50.4% over 3 years and 162.3% over 5 years may have some investors reassessing the current price and risk. Recent coverage around W. R. Berkley has mainly centered on its position within the US insurance sector and...

If you are wondering whether Par Pacific Holdings is still attractively priced after a strong run, this article will walk through what the current share price might be implying about value. The stock closed at US$37.16 recently, with returns of 3.7% over the last 7 days, a 13.4% decline over 30 days, and gains of 3.7% year to date, 113.9% over 1 year, 57.7% over 3 years, and 175.3% over 5 years. These moves have put Par Pacific on the radar of investors who are reassessing the balance...

MoonLake Immunotherapeutics (MLTX) drew investor attention after the U.S. FDA told the company that existing MIRA, VELA-1, and VELA-2 data could support a Biologics License Application for sonelokimab in hidradenitis suppurativa. See our latest analysis for MoonLake Immunotherapeutics. The FDA update arrived alongside sharp recent share price moves, with a 1-day share price return of 28.94% and 7-day return of 54.73%. The 1-year total shareholder return of 60.08% decline contrasts with a...

If you are wondering whether Darden Restaurants at around US$202 a share still offers value, this article walks through what the current price might be saying about the stock. The share price has recently shown solid momentum, with returns of 8.1% over the last 7 days, 13.0% over the past month, 8.1% year to date, 15.8% over 1 year, 49.0% over 3 years and 96.6% over 5 years. Recent coverage has focused on how investors are reassessing restaurant operators, with attention on brands that have...

If you are wondering whether JD.com at around US$29.44 is a bargain or a value trap, you are not alone. This article is here to unpack that question in plain terms. The stock has been under pressure, with returns of 0.3% decline over 7 days, 0.6% decline over 30 days, 0.3% decline year to date, 8.5% decline over 1 year, 50.3% decline over 3 years, and 63.1% decline over 5 years. This naturally raises questions about both risk and future potential. Recent coverage around JD.com has largely...

Opera Limited recently filed a US$42.54 million shelf registration for 3,000,000 American Depositary Shares tied to its employee stock ownership plan and, earlier this week, its CFO participated in the virtual 28th Annual Needham Growth Conference. Together, the fresh ESOP-related shelf capacity and high-profile investor presentation highlight Opera’s current focus on capital flexibility and deepening institutional engagement. Next, we’ll examine how the new ESOP-related shelf registration...

In recent days, Union Pacific has drawn attention as BMO Capital downgraded its rating while social media debates intensified over a possible merger with Norfolk Southern, raising questions about regulatory approval and corporate direction. What stands out is how these mixed analyst views and merger rumors are reshaping investor expectations even before any formal transaction is announced. We’ll now examine how the merger speculation and accompanying analyst caution may influence Union...

In its latest quarter, AdaptHealth reported US$820.3 million in revenue, a 1.8% year-on-year increase that surpassed analyst estimates by 2.5%, with full-year revenue guidance matching expectations despite sector labor and reimbursement pressures. Although this was the slowest revenue growth among its senior health and home care peers, AdaptHealth’s ability to beat forecasts and reaffirm guidance highlights a measure of resilience in a challenging home-based care landscape. Next, we’ll...

Why Boston Scientific’s upcoming earnings are in focus Boston Scientific (BSX) is back on investor radar as the company approaches its next earnings release, with analysts lifting earnings estimates and pointing to solid demand in electrophysiology and structural heart procedures. See our latest analysis for Boston Scientific. At a share price of US$97.64, Boston Scientific has seen a 5.33% 1 month share price return and a 109.84% 3 year total shareholder return. This suggests underlying...

AbCellera Biologics (ABCL) has drawn fresh attention after settling a dispute with Bruker Corporation that brings in a US$36 million upfront payment plus future royalties, and it has also added scientist Stephen Quake to its board. See our latest analysis for AbCellera Biologics. The recent legal settlement and board appointment come on the back of a 7 day share price return of 27.41% and a year to date share price return of 27.41%. The 1 year total shareholder return of 49.66% contrasts with...

In recent weeks, Sysco Canada was named one of Atlantic Canada's Best Places to Work 2026, while Sysco Los Angeles began distributing Beyond Oil's product, and Sysco expanded its sustainability efforts through a partnership with Welgro Produce to support local growers. Together, these developments highlight how Sysco is combining workplace culture, product innovation, and supply-chain sustainability to reinforce its role in the foodservice ecosystem. We’ll now explore how Sysco’s new...

If you are wondering whether Salesforce shares are offering fair value right now, you are not alone. Many investors are asking the same question after recent price moves. The stock last closed at US$259.94, with returns of 2.5% over the past week, a 1.6% decline over 30 days, 2.5% year to date, a 17.7% decline over 1 year and a 76.0% and 23.4% return over 3 and 5 years respectively. Recent attention on Salesforce has centered on how the company is positioning its platform and tools within...

Recently, Thor Industries highlighted ongoing headwinds from a cooler recreational vehicle cycle, elevated interest rates, and uneven consumer demand that are pressuring its business conditions. An interesting twist is management’s use of pragmatic pricing in a highly competitive market, which could weigh on near-term margins as dealers keep inventories tight. With these pressures on RV demand and pricing in mind, we’ll now examine how the recent developments shape Thor Industries’...

If you are wondering whether Viking Therapeutics is still priced for promise or if the recent excitement has cooled enough to offer better value, this article walks you through what the current price might be implying. The stock has recently given back some ground, with a 9.7% decline over the last week, a 14.8% decline over the last month, and an 18.6% decline over the past year. The 3-year and 5-year returns sit at 257.4% and 393.7% respectively. These moves sit against a backdrop of...

In recent days, UBS initiated coverage on IDEAYA Biosciences and the company reported full enrollment of its pivotal Phase 2/3 darovasertib trial in metastatic uveal melanoma, while GlaxoSmithKline opted to end their collaboration and return the Werner Helicase and Pol Theta programs by March 2026. This combination of fresh analyst attention, approaching pivotal data, and regained control of key oncology assets reshapes how investors may view IDEAYA’s pipeline breadth and future...